A randomized, parallel-dose phase 1 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.
Paul H. Cottu
Research Funding - Arno Therapeutics
Andrea Varga
No relevant relationships to disclose
Sylvie Giacchetti
No relevant relationships to disclose
Eric Leblanc
No relevant relationships to disclose
Marc Espie
No relevant relationships to disclose
Anas Gazzah
No relevant relationships to disclose
Veronique Dieras
No relevant relationships to disclose
Catherine Lhomme
No relevant relationships to disclose
Francois Marc Lokiec
Consultant or Advisory Role - Arno Therapeutics
Keyvan Rezai
Consultant or Advisory Role - Arno Therapeutics
Alice Susannah Bexon
Consultant or Advisory Role - Arno Therapeutics
Erard M. Gilles
Employment or Leadership Position - Invivis
Consultant or Advisory Role - Arno Therapeutics
Joseph Bisaha
Employment or Leadership Position - Arno Therapeutics
Stock Ownership - Arno Therapeutics
Alexander Zukiwski
Employment or Leadership Position - Arno Therapeutics
Stock Ownership - Arno Therapeutics
Jacques Bonneterre
Consultant or Advisory Role - Invivis
Honoraria - Invivis